Overview
Aureka Biotechnologies is an AI-driven drug discovery firm focused on building a comprehensive biological world model. By integrating large-scale data with advanced computational modeling, the company aims to streamline the identification and validation of new therapeutic candidates, addressing critical bottlenecks in pharmaceutical research. The venture successfully secured $100 million in a Series B funding round in August 2026. This significant capital injection is dedicated to scaling their proprietary AI platform and advancing their internal pipeline, positioning the company as a key player in the intersection of generative biological modeling and drug development.
Funding History
Aureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug Discovery
Frequently Asked Questions
- How much funding does AI Funding track for Aureka Biotechnologies?
- AI Funding tracks $100M for Aureka Biotechnologies across 1 funding round in this database.
- What does Aureka Biotechnologies do?
- Aureka Biotechnologies is an AI-driven drug discovery firm focused on building a comprehensive biological world model. By integrating large-scale data with advanced computational modeling, the company aims to streamline the identification and validation of new therapeutic candidates, addressing critical bottlenecks in pharmaceutical research. The venture successfully secured $100 million in a Series B funding round in August 2026. This significant capital injection is dedicated to scaling their proprietary AI platform and advancing their internal pipeline, positioning the company as a key player in the intersection of generative biological modeling and drug development.
- Where is Aureka Biotechnologies headquartered?
- Aureka Biotechnologies is headquartered in San Francisco, CA.
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.